1. Home
  2. CNSP vs GNPX Comparison

CNSP vs GNPX Comparison

Compare CNSP & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNS Pharmaceuticals Inc.

CNSP

CNS Pharmaceuticals Inc.

HOLD

Current Price

$5.30

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$1.81

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNSP
GNPX
Founded
2017
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
4.2M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
CNSP
GNPX
Price
$5.30
$1.81
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
21.4K
298.9K
Earning Date
11-17-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$1.71
52 Week High
$114.00
$55.00

Technical Indicators

Market Signals
Indicator
CNSP
GNPX
Relative Strength Index (RSI) 33.31 33.28
Support Level $5.15 $1.71
Resistance Level $6.17 $1.88
Average True Range (ATR) 0.59 0.21
MACD -0.16 -0.02
Stochastic Oscillator 7.54 8.17

Price Performance

Historical Comparison
CNSP
GNPX

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: